Ken Griffin Charles River Laboratories International, Inc. Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$206.39 - $268.73 $8.13 Million - $10.6 Million	39,400 Added 90.37%	83,000 $17.1 Million
Q1 2024 May 15, 2024	SELL	$203.52 - $273.43 $1.02 Million - $1.37 Million	-5,000 Reduced 10.29%	43,600 $11.8 Million
Q4 2023 Feb 14, 2024	SELL	$164.52 - $238.84 $1.37 Million - $1.98 Million	-8,300 Reduced 14.59%	48,600 $11.5 Million
Q3 2023 Nov 14, 2023	BUY	$194.44 - $217.61 $9.45 Million - $10.6 Million	48,600 Added 585.54%	56,900 $11.2 Million
Q2 2023 Aug 14, 2023	SELL	$183.71 - $210.25 $2.06 Million - $2.35 Million	-11,200 Reduced 57.44%	8,300 $1.75 Million
Q1 2023 May 15, 2023	BUY	$191.89 - $259.92 $1.36 Million - $1.85 Million	7,100 Added 57.26%	19,500 $3.94 Million
Q4 2022 Feb 14, 2023	SELL	$197.11 - $250.07 $7.1 Million - $9 Million	-36,000 Reduced 74.38%	12,400 $2.7 Million
Q3 2022 Nov 14, 2022	BUY	$182.44 - $250.54 $3.34 Million - $4.58 Million	18,300 Added 60.8%	48,400 $9.53 Million

714

51.5M

233K

236K

Ticker CRL
Exchange NYSE
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 50,863,300
Market Cap $11B
Description
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Ass...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.